Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Bionano Genomics, Inc. (BNGO)

2.89   -0.36 (-11.08%) 08-19 01:49
Open: 3.23 Pre. Close: 3.25
High: 3.29 Low: 2.835
Volume: 12,089,191 Market Cap: 839(M)
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.46 - 3.48 3.48 - 3.49
Low: 3.12 - 3.15 3.15 - 3.17
Close: 3.22 - 3.25 3.25 - 3.28

Technical analysis

as of: 2022-08-18 3:51:14 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 3.79     One year: 5.08
Support: Support1: 1.46    Support2: 1.21
Resistance: Resistance1: 3.24    Resistance2: 4.34
Pivot: 2.71
Moving Average: MA(5): 3.33     MA(20): 2.48
MA(100): 1.85     MA(250): 2.98
MACD: MACD(12,26): 0.4     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 53.8     %D(3): 62.3
RSI: RSI(14): 58
52-week: High: 6.28  Low: 1.15
Average Vol(K): 3-Month: 8,463 (K)  10-Days: 20,258 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BNGO ] has closed below upper band by 44.5%. Bollinger Bands are 226.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Headline News

Thu, 18 Aug 2022
BioNano Genomics Inc (BNGO) is lower by 1.85% Thursday In Premarket Trading - InvestorsObserver

Thu, 11 Aug 2022
Why Is Bionano Genomics (BNGO) Stock Up 20% Today? - InvestorPlace

Wed, 03 Aug 2022
BNGO, NTLA and OPTT are among pre market gainers - Seeking Alpha

Tue, 02 Aug 2022
BioNano Genomics (BNGO) Stock: Why It Increased Over 9% Today - Pulse 2.0

Mon, 01 Aug 2022
Bionano Genomics Announces Publication of Landmark Research Study in Myelodysplastic Syndrome Showing OGM Data would Result in Revised Prognostic Risk Classification or Additional Actionable Variants in 28% of Study Participants - Yahoo Finance

Thu, 28 Jul 2022
2022-07-28 | NDAQ:BNGO | Press Release | Bionano Genomics Inc. - Stockhouse

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 290 (M)
Shares Float 284 (M)
% Held by Insiders 1.9 (%)
% Held by Institutions 25.9 (%)
Shares Short 44,170 (K)
Shares Short P.Month 38,050 (K)

Stock Financials

EPS -0.33
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.98
Profit Margin (%) 0
Operating Margin (%) -471.6
Return on Assets (ttm) -20.3
Return on Equity (ttm) -33.6
Qtrly Rev. Growth 73
Gross Profit (p.s.) 0.01
Sales Per Share 0.08
EBITDA (p.s.) -0.36
Qtrly Earnings Growth 0
Operating Cash Flow -106 (M)
Levered Free Cash Flow -59 (M)

Stock Valuations

PE Ratio -8.68
PEG Ratio 0
Price to Book value 2.9
Price to Sales 35.34
Price to Cash Flow -7.75

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.